The Prince Charles Hospital
15
3
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.7%
1 terminated/withdrawn out of 15 trials
88.9%
+2.4% vs industry average
20%
3 trials in Phase 3/4
25%
2 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
Role: collaborator
Artificial Intelligence in Aortic Regurgitation
Role: collaborator
The EXCEL Registry of Patients Requiring ECMO
Role: collaborator
Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis
Role: collaborator
The SHIELD Study-silicosis
Role: collaborator
Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease
Role: collaborator
A Study to Evaluate the Potential of Mesenchymal Stromal Cells to Treat Obliterative Bronchiolitis After Lung Transplantation
Role: lead
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Role: collaborator
Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3
Role: lead
Extracorporeal Membrane Oxygenation Physical Training
Role: collaborator
Hookworm Therapy for Coeliac Disease
Role: collaborator
Building Research Initiative Group: Chronic Illness Management and Adherence in Transplantation
Role: collaborator
A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis
Role: lead
Desensitising Celiac Disease Patients With the Human Hookworm
Role: lead
Tirofiban and Enoxaparin in High Risk Coronary Intervention
Role: lead
All 15 trials loaded